FDA rejects Singulair-Claritin combination

Apr 30, 2008

The U.S. Food and Drug Administration rejected a proposed pill that would combine the drugs Claritin and Singular, Schering-Plough said.

The drug, a combination of loratadine and montelukast developed in a joint venture between Schering-Plough and Merck Pharmaceuticals, was targeted for patients with allergic rhinitis symptoms and nasal congestion.

The active ingredients of Claritin is loratadine and the active ingredient of Singulair is montelukast sodium. Both drugs are indicated for the relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the two drug companies said in a statement.

The companies did not explain the FDA's reason for rejecting the drug combo.

Copyright 2008 by United Press International

Explore further: Medical charity accuses US of pushing India to ease patent rules

add to favorites email to friend print save as pdf

Related Stories

Asthma drug prevents spread of breast cancer: study

Nov 03, 2010

A drug commonly used in Japan and Korea to treat asthma has been found to stop the spread of breast cancer cells traditionally resistant to chemotherapy, according to a new study led by St. Michael's pathologist Dr. Gerald ...

Munich researchers discover key allergy gene

Aug 22, 2008

Together with colleagues from the Department of Dermatology and Allergy and the Center for Allergy and Environment of the Technische Universität München, scientists at the Helmholtz Zentrum München have pinpointed a major ...

Hay fever can send work productivity down the drain

Apr 26, 2007

Employers can blame hay fever for the loss of millions of hours of work productivity this spring. A new study of nearly 600 people with hay fever symptoms, including sneezing, watery eyes and runny and itchy noses, found ...

Recommended for you

No added benefit proven for umeclidinium/vilanterol in COPD

4 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

User comments : 0